Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AAV2-sFLT01 · 1 trial · 10 indications
| Arm | Type | Description |
|---|---|---|
| 2 x 10^8 vector genomes (vg) AAV2-sFLT01 | EXPERIMENTAL | - |
| 2 x 10^9 vector genomes (vg) AAV2-sFLT01 | EXPERIMENTAL | - |
| 6 x 10^9 vector genomes (vg) AAV2-sFLT01 | EXPERIMENTAL | - |
| 2 x 10^10 vector genomes (vg) AAV2-sFLT01 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| AAV2-sFLT01 | BIOLOGICAL | 2 x 10\^8 vector genomes (vg) AAV2-sFLT01. Single intravitreal injection to a single eye, using a fixed volume of 100 μL. |
Inclusion Criteria: * Choroidal neovascular membrane (CNV) secondary to AMD, as confirmed by the patient's medical history and a documented diagnosis of CNV. * Distance BCVA of 20/100 or worse in the study eye. * The fellow eye must have distance BCVA of 20/400 or better. * The study eye, i.e., the...
AAV2-sFLT01 is an investigational gene therapy being studied for the treatment of neovascular age-related macular degeneration (AMD), a condition that causes vision loss due to abnormal blood vessel growth in the retina. It is administered to patients aged 50 years and older and is currently in clinical development.
AAV2-sFLT01 is designed to deliver a gene that encodes a soluble form of the vascular endothelial growth factor (VEGF) receptor, known as sFLT01. This protein is intended to bind to VEGF and inhibit its activity, thereby reducing abnormal blood vessel growth in the eye associated with neovascular age-related macular degeneration.
AAV2-sFLT01 is being developed by Sanofi, a multinational pharmaceutical company listed on the stock exchange under the ticker symbol SNY. The company is conducting clinical research to evaluate the safety and tolerability of this gene therapy for patients with neovascular age-related macular degeneration.
AAV2-sFLT01 is in Phase 1 clinical development. It is an investigational therapy that has not yet been approved by regulatory authorities. The Phase 1 trial has been completed, and the therapy remains under investigation for its safety and tolerability in patients with neovascular age-related macular degeneration.
AAV2-sFLT01 has been studied in one completed Phase 1 clinical trial with the identifier NCT01024998. This trial, titled 'Safety and Tolerability Study of AAV2-sFLT01 in Patients With Neovascular Age-Related Macular Degeneration (AMD),' enrolled 19 participants in the United States and was a controlled study.
AAV2-sFLT01 is a gene therapy that uses an adeno-associated virus (AAV) vector to deliver the sFLT01 gene, which encodes a soluble VEGF receptor. It is specifically designed for the treatment of neovascular age-related macular degeneration and is being developed by Sanofi under this name.